EGFR and neoplasm: However, despite the initial response to EGFR kinase inhibitors, virtually all the EGFR-mutant patients eventually experience recurrence (9) due to the sustained TKI-insensitive EGFR signaling in the TKI-treated tumors, leading to recurrent tumor resistance (12).